Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Q2 2022 Earnings Presentation

30 slides from Reata Pharmaceuticals's earnings presentation, Aug 8, 2022

  1. Slide 1: 2nd Quarter 2022 Financial Results and Update on Clinical Development Programs

    2nd Quarter 2022 Financial Results and Update on Clinical Development Programs August 8, 2022 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including statements reg

  3. Slide 3: Today's Agenda

    Today’s Agenda Opening Remarks | Warren Huff, CEO Development Update | Colin Meyer, MD, Chief Innovation Officer Commercial Update | Dawn Bir, Chief Commercial Officer Financial & Operational Update | Manmeet Soni, President Concluding Remarks | Warren Huff, CEO

  4. Slide 4: Update on Omaveloxolone Program in Friedreich's Ataxia

    Update on Omaveloxolone Program in Friedreich’s Ataxia NDA: New Drug Application; FDA: United States Food & Drug Administration; PDUFA: Prescription Drug User Fee Act 2Q21 FDA suggests Pre-NDA meeting to discuss program 4Q21 FDA granted Fast Track Designation and Rolling NDA submission/review 2Q22 N

  5. Slide 5: Single Trial Regulatory Pathways Challenging to Meet in Rare Diseases Like FA

    Single Trial Regulatory Pathways Challenging to Meet in Rare Diseases Like FA One Adequate and Well-Controlled Clinical Trial with Statistically Very Persuasive, Compelling Results Omaveloxolone Regulatory Path One Adequate and Well-Controlled Clinical Trial Plus Confirmatory Evidence FDA guidance1

  6. Slide 6: MOXIe Part 2 Pivotal Trial of Omaveloxolone in FA

    MOXIe Part 2 Pivotal Trial of Omaveloxolone in FA MOXIe Part 2, one of the largest completed global interventional studies in patients with FA, met mFARS primary endpoint (p=0.014) Improvement observed in all subsections relative to placebo Major subgroups and all analysis populations favored omavel

  7. Slide 7: Mid-Cycle Communication Meeting Agenda and Discussion

    Mid-Cycle Communication Meeting Agenda and Discussion FDA comments from recent mid-cycle communication meeting are similar to prior feedback Continue to have concerns regarding the strength of efficacy evidence No new significant issues raised by FDA No significant clinical safety issues identified

  8. Slide 8: Mid-Cycle Communication Meeting: Submitted Additional Supporting Evidence of Efficacy

    Mid-Cycle Communication Meeting Submitted Additional Supporting Evidence of Efficacy FDA agreed, and we have since submitted the following updated and new efficacy data FDA draft guidance - Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, December 2019 Conf

  9. Slide 9: Omaveloxolone in Friedreich's Ataxia

    Omaveloxolone in Friedreich’s Ataxia

  10. Slide 10: Delayed-Start Analysis: March 2022 Update

    Delayed-Start Analysis: March 2022 Update to Address Interpretability of the Delayed-Start Analysis NDA amendment for Delayed-Start Analysis uses data from March 2022 data cut off Updated analysis provides additional data at later time points and Extension Week 144 Separation observed at Week 48 of

  11. Slide 11: Post Hoc Propensity-Matched Analysis: External Natural History Control Group

    Post Hoc Propensity-Matched Analysis Use of External Natural History Control Group Confirmatory evidence could include comparison to reliable, systematically collected and well documented natural history of patients with the disease FDA draft guidance - Demonstrating Substantial Evidence of Effectiv

  12. Slide 12: FA-COMS: Prospective, High Quality Natural History Study in FA

    FA-COMS: Prospective, High Quality Natural History Study in FA FA-COMS is an ongoing, global, multicenter, longitudinal, prospective, observational study in FA1 Enrolled more than 1,250 patients with FA Collecting quantitative serial clinical data including mFARS Patients are assessed annually and f

  13. Slide 13: Propensity-Matched Analysis: Propensity Score Matching

    Propensity-Matched Analysis Propensity Score Matching Propensity scores calculated based on factors prognostic to disease progression Baseline covariates prognostic for disease progression selected in collaboration with FA-COMS PI and statistician Propensity scores calculated based on age, age at FA

  14. Slide 14: Propensity-Matched Analysis: Comparable Baseline Characteristics

    Propensity-Matched Analysis Comparable Baseline Characteristics Demographics and baseline characteristics balanced between the two groups Median treatment/follow-up duration of approximately 3 years Characteristic Statistic Matched FA-COMS (n=136) MOXIe Extension (n=136) Age (years) Mean (SD) 26.2 (

  15. Slide 15: Propensity-Matched Analysis: Primary Pooled Population

    Propensity-Matched Analysis Primary Pooled Population Patients in the matched FA-COMS group progressed 6.61 mFARS points at Year 3 vs. 3.00 mFARS points for patients treated with omaveloxolone in MOXIe Extension for a difference of -3.61 mFARS points (nominal p=0.0001) mFARS progression 55% slower i

  16. Slide 16: Propensity-Matched Analysis: Placebo-to-Omaveloxolone and Omaveloxolone-to-Omaveloxolone

    Propensity-Matched Analysis: Placebo-to-Omaveloxolone and Omaveloxolone-to-Omaveloxolone Similar change in mFARS observed at Year 3 relative to matched FA-COMS patients in subsets based on prior treatement1 Placebo-to-Omaveloxolone: difference of -4.09 mFARS points (nominal p=0.0001)2 Omaveloxolone-

  17. Slide 17: Mechanistic Support for Omaveloxolone in FA

    Mechanistic Support for Omaveloxolone in FA A single adequate and well-controlled clinical investigation can be supported by data that provide strong mechanistic support Well-understood disease pathophysiology Mechanistic evidence obtained from relevant and well understood pharmacodynamic endpoint o

  18. Slide 18: Impaired Mitochondrial Function Associated with Worsening Neurological Function in FA

    Impaired Mitochondrial Function Associated with Worsening Neurological Function in Friedreich’s Ataxia Mitochondrial function and ATP production are reduced in FA patients Lower maximal mitochondrial respiration and spare respiratory capacity in FA patient fibroblasts1 Lower ATP production observed

  19. Slide 19: Mechanism of Action: Nrf2 Suppression Contributes to Pathophysiology of FA

    Mechanism of Action: Nrf2 Suppression Contributes to Pathophysiology of Friedreich’s Ataxia Frataxin deficiency associated with impaired mitochondrial energy production Nrf2 levels and target gene expression suppressed in FA patient fibroblasts Nrf2 directly regulates mitochondrial energy production

  20. Slide 20: Mechanism of Action: Nrf2 Levels and Mitochondrial Function Restored in FA Fibroblasts

    Nrf2 protein levels in FA patient fibroblasts restored to levels seen in healthy fibroblasts Dose dependent increases in Nrf2 targets observed in patient fibroblasts treated with omaveloxolone Omaveloxolone restored mitochondrial energy production in FA disease models and patient samples Mechanism o

  21. Slide 21: Mechanism of Action: mFARS Improvements Associated with Induction of Nrf2

    Mechanism of Action: mFARS Improvements Associated with Induction of Nrf2 Least Improved mFARS Most Improved mFARS Dose-dependent increases in Nrf2 targets, ferritin and GGT, observed in patients treated with omaveloxolone in MOXIe Part 1 Induction of Nrf2 targets associated with mFARS improvements

  22. Slide 22: Safety and Summary of Efficacy and Safety Evidence

    Safety Well tolerated with few discontinuations or serious adverse events Fewer cardiovascular AEs, no increases in BP, no findings on serial ECGs or ECHOs No new safety findings in the ongoing MOXIe Extension Study Summary of Efficacy and Safety Evidence MOXIe Part 2 2.4 point improvement in mFARS

  23. Slide 23: Commercial Update

    Commercial Update

  24. Slide 24: Commercial Launch Operations Preparing for Launch Execution in Early 2023

    Commercial Launch Operations Preparing for Launch Execution in Early 2023 ThinkFA.com HCP disease education website focused on FA recognition, diagnosis, severity Digital HCP Campaign Omnichannel digital campaign drives HCP traffic to ThinkFA.com Launch preparation continues to advance with regulato

  25. Slide 25: Financial & Operational Update

    Financial & Operational Update

  26. Slide 26: Financial Summary

    Financial Summary 1Excludes stock-based compensation expenses; 2Excludes various adjustments, including stock-based compensation expenses, non-cash interest expense from liability related to sale of future royalties; see the next slide for a reconciliation between GAAP and non-GAAP measures. GAAP: G

  27. Slide 27: Reconciliation of GAAP to Non-GAAP Financial Measures

    Reconciliation of GAAP to Non-GAAP Financial Measures

  28. Slide 28: Concluding Remarks

    Concluding Remarks

  29. Slide 29: Reata at a Glance

    Reata at a Glance NDA for omaveloxolone in FA Accepted for filing with Priority Review Mid-cycle meeting completed Preparing for AdCom PDUFA Nov. 30, 2022 Plan to submit MAA for omaveloxolone in the fourth quarter of 2022 FALCON Phase 3 trial in ADPKD ongoing with more than 580 patients enrolled Req

  30. Slide 30: Thank you

    Thank you

Reata Pharmaceuticals — Q2 2022 Earnings Presentation on 6ix